Estrogen receptor expression in type 1 endometrial cancer and its association with lymphovascular space invasion
DOI:
https://doi.org/10.13181/mji.oa.257842Keywords:
endometrial cancer, estrogen receptor, lymphovascular invasionAbstract
BACKGROUND Endometrial cancer (EC) ranks sixth in female genital malignancy and originates in the endometrial lining. Estrogen receptor (ER) expression is important in EC prognosis and recurrence, influenced by the presence of lymphovascular space invasion (LVSI). This study aimed to determine the association between ER expression and LVSI in type 1 EC.
METHODS A retrospective analysis was conducted on 135 patients with type 1 EC who underwent surgery at the Cipto Mangunkusumo Hospital, Jakarta, Indonesia, between January 2012 and December 2022. Immunohistochemistry (IHC) with ER antibodies was performed on all samples in April 2023. ER expression was evaluated using the Allred scoring system, and its association between ER expression (percentage and intensity stain) and LSVI was statistically analyzed.
RESULTS Of 135 samples, 44 (32.6%) were LVSI-positive. No significant association was found between IHC percentage stain and LVSI (p = 0.994). However, a significant association was found between IHC stain intensity and LVSI-positive in patients with type 1 EC (p = 0.022). ER intensity score 2 had a higher LVSI risk compared to score 1 and score 3 (from 51%, 26%, and 26%, respectively).
CONCLUSIONS ER expression is associated with LVSI of type 1 EC. While IHC stain percentage showed no correlation with LVSI, stain intensity was significantly linked to LVSI-positive in patients with type 1 EC. Regular assessment of ER expression can provide significant prognostic information, support hormonal therapy, and identifying clinical characteristics of tumors.
Downloads
References
Höhn AK, Brambs CE, Hiller GG, May D, Schmoeckel E, Horn LC. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 2021;81(10):1145-53. https://doi.org/10.1055/a-1545-4279
Yidong GE, Xiaoqi NI, Jingyun LI, Meng YE, Xiaofeng JIN. Roles of estrogen receptor α in endometrial carcinoma (Review). Oncol Lett. 2023;26(6):1-1. https://doi.org/10.3892/ol.2023.14117
Waluyo ST, Tjokroprawiro BA, Rahaju AS. Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics. Cancer Treat Res Commun. 2023;37:100766. https://doi.org/10.1016/j.ctarc.2023.100766
Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, Gil-Moreno A, Cabrera S, Colas E. Prognostic biomarkers in endometrial cancer: a systematic review and meta-analysis. J Clin Med. 2020;9(1900):1-20. https://doi.org/10.3390/jcm9061900
Restaino S, Tortorella L, Dinoi G, Zannoni GF, Baroni A, Capasso I, et al. Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: prognostic and clinical implications. Eur J Cancer. 2021;142(1):29-37. https://doi.org/10.1016/j.ejca.2020.10.011
Singh N, Hirschowitz L, Zaino R, Alvarado-Cabrero I, Duggan MA, Ali-Fehmi R, et al. Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). Int J Gynecol Pathol. 2019;38(1):1-5. https://doi.org/10.1097/PGP.0000000000000524
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474-81. https://doi.org/10.1200/JCO.1999.17.5.1474
Vermij L, Jobsen JJ, León-Castillo A, Brinkhuis M, Roothaan S, Powell ME, et al. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. Br J Cancer. 2023;128(7):1360-8. https://doi.org/10.1038/s41416-023-02141-0
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95. https://doi.org/10.1200/JCO.2009.25.6529
Siegenthaler F, Epstein E, Büchi CA, Gmür A, Saner FA, Rau TT, et al. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer. Int J Gynecol Cancer. 2023;33(11):1702-7. https://doi.org/10.1136/ijgc-2023-004606
Tortorella L, Restaino S, Zannoni GF, Vizzielli G, Chiantera V, Cappuccio S, et al. Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J Gynecol Oncol. 2021;32(2):1-9. https://doi.org/10.3802/jgo.2021.32.e11
Watanabe T, Honma R, Kojima M, Nomura S, Furukawa S, Soeda S, et al. Prediction of lymphovascular space invasion in endometrial cancer using the 55-gene signature selected by DNA microarray analysis. PLoS One. 2019;14(9):1-10. https://doi.org/10.1371/journal.pone.0223178
Hill DA, Barry M, Wiggins C, Nibbe A, Royce M, Prossnitz E, et al. Estrogen receptor quantitative measures and breast cancer survival. Breast Cancer Res Treat. 2017;166(3):855-64. https://doi.org/10.1007/s10549-017-4439-6
Lorenzini J, Deberti M, Body G, Carcopino X, Touboul C, Dabi Y, et al. Lymphovascular space invasion and estrogen receptor status in high-grade serous ovarian cancer - A multicenter study by the francogyn group. J Gynecol Obstet Hum Repro. 2022;51(1):1-5. https://doi.org/10.1016/j.jogoh.2021.102242
Eminović S, Babarović E, Klarić M, Fučkar Čupić D. Blood vessel invasion is an independent prognostic factor in endometrial endometrioid carcinoma compared to lymph vessel invasion and myometrial invasion pattern. Cancers (Basel). 2024;16(13):1. https://doi.org/10.3390/cancers16132385
Kim Y, Aiob A, Kim H, Suh DH, Kim K, Kim YB, et al. Clinical implication of pd-l1 expression in patients with endometrial cancer. Biomedicines. 2023;11(10):1-10. https://doi.org/10.3390/biomedicines11102691
Ren S, Wu J, Yin W, Liao Q, Gong S, Xuan B, et al. Researches on the correlation between estrogen and progesterone receptors expression and disease-free survival of endometrial cancer. Cancer Manag Res. 2020;12(1):12635-47. https://doi.org/10.2147/CMAR.S263219
Christina S, Setyaningsih CK, Kunci K. Correlation miometrial invasion with limfovascular invasion and histologic grade in endometrial carcinoma. J Kedokteran Yarsi. 2019;27(3):132-43. https://doi.org/10.33476/jky.v27i3.1204
Shopov S. Papillary endometrioid carcinoma of intermediate grade with infiltration in a leiomyoma. Folia Med. 2020;62(1):190-4. https://doi.org/10.3897/folmed.62.e49813
Waluyo ST, Tjokroprawiro BA, Rahaju AS. Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer. Eur J Obstet Gynecol Reprod Biol X [Internet]. 2024;21:100293. Available from: https://doi.org/10.1016/j.eurox.2024.100293. https://doi.org/10.1016/j.eurox.2024.100293
Michalczyk K, Cymbaluk-Płoska A. Metalloproteinases in endometrial cancer-are they worth measuring? Int J Mol Sc. 2021;22(22):1-10. https://doi.org/10.3390/ijms222212472
Kampf C, Mardinoglu A, Fagerberg L, Hallström BM, Edlund K, Lundberg E, et al. The human liver-specific proteome defined by transcriptomics and antibody-based profiling. FASEB Journal. 2014;28(7):2901-14. https://doi.org/10.1096/fj.14-250555
Vrede SW, Van Weelden WJ, Bulten J, Gilks CB, Teerenstra S, Huvila J, et al. Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer. Gynecol Oncol. 2025;192:15-23. https://doi.org/10.1016/j.ygyno.2024.10.028
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Wiwit Ade Fidiawati, Andrijono, Nurjati Chairani Siregar, Joedo Prihartono, Gatot Purwoto, Tantri Hellyanti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
